Last reviewed · How we verify
Flurbiprofen 10%
At a glance
| Generic name | Flurbiprofen 10% |
|---|---|
| Also known as | Flurbiprofen |
| Sponsor | Express Specialty Pharmacy |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma (PHASE4)
- To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (PHASE1)
- Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care (PHASE1, PHASE2)
- To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects (PHASE1)
- Pharynx Analgesia Before Upper Gastrointestinal Endoscopy (NA)
- Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flurbiprofen 10% CI brief — competitive landscape report
- Flurbiprofen 10% updates RSS · CI watch RSS
- Express Specialty Pharmacy portfolio CI